Mitochondrial DNA depletion, oxidative stress, and mutation: Mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors

Laboratory Investigation

Volumn 81, Issue 6, 2001, Pages 777-790

  Lewis, William ^a   Copeland, William C ^b   Day, Brian J ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOVIR; DNA POLYMERASE; FIALURIDINE; GENE PRODUCT; LAMIVUDINE; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS PROTEIN; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CATALYSIS; DNA DAMAGE; DNA REPLICATION; HYPOTHESIS; MUTATION; MYOPATHY; OXIDATIVE STRESS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL RATE;

EID: 0034979438     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780288     Document Type: Short Survey

References (165)

1. Oxidants, antioxidants, and the degenerative diseases of aging
2. Peripheral neuropathy induced by 2′,3′-dideoxycytidine. A rabbit model of 2′,3′-dideoxycytidine neurotoxicity
3. Mitochondrial schwannopathy and peripheral myelinopathy in a rabbit model of dideoxycytidine neurotoxicity
4. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy
5. Immunolocalization of cellular glutathione peroxidase in adult rat lungs and quantitative analysis after postembedding immunogold labeling
6. Mechanisms of toxicity of 3′-azido-3′-deoxythymidine. Its interaction with adenylate kinase
7. 3′-Azido-3′-deoxythmidine uptake into isolated rat liver mitochondria and impairment of ADP/ATP translocator
8. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly
9. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddl) and zalcitabine (ddC) on cultured human muscle cells
10. 2′,3′-dideoxycytidine (ddC) toxic neuropathy: A study of 52 patients
11. Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC
12. What is oxidative stress?
13. Hyperlactatemia and antiretroviral therapy in the Swiss HIV Cohort Study (SHCS)
14. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen
15. Deaths in US fialuridine trial
16. DNA strand scission by enzymically generated oxygen radicals
17. Mitochondrial toxicity induced by nucleoside-analogue reverse- transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
18. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
19. Nitric oxide as a competitive inhibitor of oxygen consumption in the mitochondrial respiratory chain
20. 2′ ,3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: A phase I trial
21. 2 injury
22. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
23. The accessory subunit of Xenopus laevis mitochondrial DNA polymerase gamma increases processivity of the catalytic subunit of human DNA polymerase gamma and is related to class II aminoacyl-tRNA synthetases
24. Partial cytochrome c oxidase deficiency and cytoplasmic bodies in patients with zidovudine myopathy
25. Determination of the blood lactate: Pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathy
26. Lactic acidosis complicating the acquired immunodeficiency syndrome
27. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine
28. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2′,3′;-dideoxycytidine
29. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity
30. Kinetic interaction of the diphosphates of 9-(2-phosphonyl-methoxyethyl) adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases alpha, beta and gamma
31. Near-fatal metabolic acidosis, liver failure in mitochondrial (mt) DNA depletion in an HIV-infected child treated with combination antiretroviral therapy (ART)
32. Once-daily administration of 2′,3′-dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial
33. Histochemical and ultrastructural changes induced by zidovudine in mitochondria of rat cardiac muscle
34. Hepatic Morphological alterations induced by zidovudine (ZDV) in an experimental model
35. Degeneration of human oncogenes and mitochondrial genes occurs in cells that exhibit age-related pathology
36. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells
37. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells
38. Exacerbation of peripheral neuropathy by lamivudine
39. Mitochondrial myopathy caused by long-term zidovudine therapy
40. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage
41. Dilated cardiomyopathy in a zidovudine-treated AIDS patient
42. Zidovudine causes early increases in mitochondrial ribonucleic acid abundance and induces ultrastructural changes in cultured mouse muscle cells
43. In search of a selective antiviral chemotherapy
44. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins
45. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus
46. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2′,3′-dideoxycytidine (ddC)
47. Differential effects of zidovudine and zidovudine triphosphate on mitochondrial permeability transition and oxidative phosphorylation
48. Efficient incorporation of anti-HIV deoxynucleotides by recombinant yeast mitochondrial DNA polymerase
49. Schwann cell mitochondrial alterations in peripheral nerves of rabbits treated with 2′,3′-dideoxycytidine
50. Ultrastructure of peripheral neuropathy induced in rabbits by 2′,3′-dideoxycytidine
51. Is cell aging caused by respiration-dependent injury to the mitochondrial genome?
52. The inactivation of Fe-S cluster containing hydro-lyases by superoxide
53. Inhibitory effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks
54. Hyperoxia increases oxygen radical production in rat lungs and lung mitochondria
55. Inactivating DNA alterations induced by peroxides and peroxide-producing agents
56. Hepatomegaly with severe steatosis in HIV-seropositive patients
57. Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3′-azido-3′-deoxythymidine
58. Purification and identification of subunit structure of the human mitochondrial DNA polymerase
59. The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma
60. Zidovudine intolerance
61. The importance of free radicals and catalytic metal ions in human diseases
62. Cellular and molecular mechanisms of endothelial cell dysfunction
63. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma
64. Age-dependent increase in deleted mitochondrial DNA in the human heart: Possible contributory factor to presbycardia
65. Randomized trial of continued Indinavir (IDV)/ZDV/3TC vs switch to IDV/ddl/d4T or IDV/ddl/d4T + hydroxyurea in patients with viral suppression
66. Age-associated oxygen damage and mutations in mitochondrial DNA in human hearts
67. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: A report of six cases
68. Major growth reduction and minor decrease in mitochondrial enzyme activity in cultured human muscle cells after exposure to zidovudine
69. Cellular targets of 3′-azido-3′-deoxythymidine: An early (non-delayed) effect on oxidative phosphorylation
70. The Friend murine erythroleukemia cell, a model system for studying the association between bone marrow toxicity induced by 3′-azido-3′-dideoxythymidine and dideoxynucleoside inhibition of mtDNA replication
71. DNA polymerase gamma from Xenopus laevis. I. The identification of a high molecular weight catalytic subunit by a novel DNA polymerase photolabeling procedure
72. The 5′-triphosphates of 3′-azido-3′-deoxythymidine and 2′, 3′-dideoxynucleosides inhibit DNA polymerase gamma by different mechanisms
73. Myopathies and neuropathies in HIV-infected adults and children
74. Reye's syndrome in adult with AIDS
75. Structural and catalytic features of the mitochondrial DNA polymerase from Drosophila melanogaster embryos
76. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity
77. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy
78. Is the failing heart energy depleted?
79. Antihuman immunodeficiency virus type 1 therapy and peripheral neuropathy: Prevention of 2′,3′-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate
80. Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2′-fluoro-2′-deoxy-beta-Darabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells
81. Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma
82. Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues
83. Exonucleolytic proofreading by a mammalian DNA polymerase
84. Exonucleolytic proofreading enhances the fidelity of DNA synthesis by chick embryo DNA polymerase-gamma
85. 2′,3′-dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial
86. Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model
87. Combination antiretroviral therapy. Back to the future
88. The thymidine analogs fialuridine and zidovidine inhibit mitochondrial energy metabolism in cultured hepatoblasts
89. Pathologic changes in the hearts of patients with AIDS
90. Mitochondrial toxicity of antiviral drugs
91. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria
92. Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax)
93. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
94. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts
95. Mammalian DNA polymerases alpha, beta, gamma, delta, and epsilon incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU Triphosphate
96. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts
97. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine
98. Triphosphorylated fialuridine and metabolites inhibit cardiac mitochondrial DNA polymerase gamma (DNA polymerase-gamma): Alternative substrates for thymidine triphosphate (dTTP)
99. Differential incorporation and removal of anti-viral deoxynucleotides by human DNA polymerase
100. The mitochondrial p55 accessory subunit of human DNA polymerase gamma enhances DNA binding, promotes processive DNA synthesis, and confers N-ethylmaleimide resistance
101. Mitochondrial DNA mutations as an important contributor to aging and degenerative diseases
102. Mitochondrial DNA mutation and the aging process: Bioenergy and pharmacological intervention
103. Absence of cardiac toxicity of zidovudine in infants
104. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine
105. Hyperlactatemia in 20 patients receiving NRTI combination regimens
106. Properties of the 3′ to 5′ exonuclease associated with porcine liver DNA polymerase gamma. Substrate specificity, product analysis, inhibition, and kinetics of terminal excision
107. US agencies split over inquiry into effects of radiation experiments
108. Role of glutathione peroxidase and phospholipid hydroperoxide glutathione peroxidase in the reduction of lysophospholipid hydroperoxides
109. Hepatitis study. Drug trial deaths deemed unavoidable
110. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis
111. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides
112. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study
113. Dideoxynucleoside triphosphates inhibit mitochondrial DNA polymerase-γ: Comparison of zidovudine and didanosine
114. An update on the mitochondrial-DNA mutation hypothesis of cell aging
115. AZT causes tissue-specific inhibition of mitochondrial bioenergetic function
116. Differences in anion gap with different nucleoside RTl combinations
117. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea
118. mtDNA depletion with variable tissue expression: A novel genetic abnormality in mitochondrial diseases
119. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity
120. Cytochrome-c-oxidase deficient cardiomyocytes in the human heart: An age-related phenomenon. A histochemical ultracytochemical study
121. Mitochondrial formation of QH Radicals by an ubisemiquinone-dependent reaction an alternative pathway to the iron-catalysed Haber-Weiss cycle
122. AZT incorporation into mitochondria: Study in a human myeloid cell line
123. Mitochondrial toxicity of NRTI analogs
124. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′,3′-dideoxyguanosine and 3′-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs
125. DNA replication fidelity with 8-oxodeoxyguanosine triphosphate
126. Mitochondrial sensitivity to AZT
127. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS
128. Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies
129. Efficient repair of abasic sites in DNA by mitochondrial enzymes
130. Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide
131. Zidovudine mitochondriopathy of hamster quadriceps muscle
132. Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration
133. Do mitochondrial DNA fragments promote cancer and aging?
134. Normal oxidative damage to mitochondrial and nuclear DNA is extensive
135. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
136. Mitochondrial function in neurodegeneration and ageing
137. Nuclear and mitochondrial changes of co-cultivated spinal cord, spinal ganglia and muscle fibers following treatment with various doses of zidovudine
138. The effect of L-carnitine on the AZT-induced destruction of human myotubes. Part II: Treatment with L-carnitine improves the AZT-induced changes and prevents further destruction
139. Mitochondrial DNA diseases: Histological and cellular studies
140. Studies on the inhibition of mitochondrial DNA replication by 3′-azido-3′-deoxythymidine and other dideoxynucleoside analogs which inhibit HIV-1 replication
141. Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy
142. Base modification and strand breakage in isolated calf thymus DNA and in DNA from human skin epidermal keratinocytes exposed to peroxynitrite or 3-morpholinosydnonimine
143. Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection
144. Aortas from NL4-3 gag/pol AIDS mice have impaired endothelium-dependent relaxation
145. Mitochondrial toxicity: New adverse drug effects
146. Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat
147. Evaluation of the relative contribution of nitric oxide and peroxynitrite to the suppression of mitochondrial respiration in immunostimulated macrophages using a manganese mesoporphyrin superoxide dismutase mimetic and peroxynitrite scavenger
148. Mitochondrial iron not bound in heme and iron-sulfur centers. Estimation, compartmentation and redox state
149. Reactive oxygen species produced by liver mitochondria of rats in sepsis
150. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection
151. Four cases of fatal lactic acidosis due to mitochondrial toxicity of NRTI treatment: Analysis of clinical features and risk factors
152. Myopathy with human immunodeficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine?
153. Effect of anti-HIV 2′-beta-fluoro-2′,3′-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production
154. 2 release by lung mitochondria and microsomes
155. Diseases of the mitochondrial DNA
156. Mitochondrial genetics: A paradigm for aging and degenerative diseases?
157. Zidovudine and dideoxynucleosides deplete wild-type mitochondrial DNA levels and increase deleted mitochondrial DNA levels in cultured Kearns-Sayre syndrome fibroblasts
158. Accessory subunit of mitochondrial DNA polymerase from Drosophila embryos. Cloning, molecular analysis, and association in the native enzyme
159. A mitochondrial DNA polymerase from embryos of Drosophila melanogaster. Purification, subunit structure, and partial characterization
160. Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases
161. Deoxyribonucleotide analogs as inhibitors and substrates of DNA polymerases
162. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress
163. Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex